Cefdinir: Difference between revisions
(→Source) |
ClaireLewis (talk | contribs) No edit summary |
||
(15 intermediate revisions by 7 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: Third generation [[cephalosporin]] | ||
*Dosage Forms: | *Dosage Forms: capsule, oral suspension | ||
*Common Trade Names: | *Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL | ||
*Routes of Administration: PO | |||
*Common Trade Names: Omnicef | |||
==Adult Dosing== | ==Adult Dosing== | ||
*600mg/d divided q12-24hrs for 10 days for [[CAP]], chronic [[bronchitis]], acute [[sinusitis]], [[strep pharyngitis]], [[cellulitis]] | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Probably safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD | ||
**Pediatric | **Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD | ||
*Hepatic | *Hepatic dosing not defined | ||
==Contraindications== | ==Contraindications== | ||
Line 25: | Line 27: | ||
===Common=== | ===Common=== | ||
*Diarrhea | |||
*[http://genericpharmaceuticals.science/cefdinir-colored-stool/ Stool discoloration] which is guiac negative and returns to normal color after cessation | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 100 min | ||
*Metabolism: | *Metabolism: Not appreciably metabolized | ||
*Excretion: | *Excretion: Urine (7-25% as unchanged drug) | ||
*Mechanism of Action: | *Mechanism of Action: Bactericidal, inhibits bacterial cell wall synthesis | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Line 155: | Line 159: | ||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | |||
== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] [[Category:ID]] |
Revision as of 21:48, 19 September 2019
General
- Type: Third generation cephalosporin
- Dosage Forms: capsule, oral suspension
- Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
- Routes of Administration: PO
- Common Trade Names: Omnicef
Adult Dosing
- 600mg/d divided q12-24hrs for 10 days for CAP, chronic bronchitis, acute sinusitis, strep pharyngitis, cellulitis
Pediatric Dosing
- 14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day
Special Populations
- Pregnancy Rating: B
- Lactation: Probably safe
- Renal Dosing
- Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
- Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
- Hepatic dosing not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Diarrhea
- Stool discoloration which is guiac negative and returns to normal color after cessation
Pharmacology
- Half-life: 100 min
- Metabolism: Not appreciably metabolized
- Excretion: Urine (7-25% as unchanged drug)
- Mechanism of Action: Bactericidal, inhibits bacterial cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014